Etelcalcetide vs Cinacalcet Treatment Adherence Examined
Secondary hyperparathyroidism remains uncontrolled in many patients with chronic kidney disease.
Diagnosis & Disease Information
Earlier Calcimimetic Use May Allow Better PTH Control in Hemodialysis
Recent studies have shown the importance of starting treatment at lower phosphorus and PTH levels on long-term outcomes of SHPT.
Parathyroidectomy Increasing in the United States
Despite the increasing availability of calcimimetics, parathyroidectomy rates in the US have gradually increased.
Post-Parathyroidectomy Hypocalcemia Risk Factors Identified
Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring.
CKD-MBD Marker Changes Vary Across Dialysis Modalities
Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.
Etelcalcetide Effective in Cases Where Cinacalcet Is Problematic
Switching from oral to intravenous calcimimetic may lower PTH levels in patients on hemodialysis with poor tolerance.
Hyperuricemia May Be Linked to SHPT in Chronic Kidney Disease
The mechanism by which hyperuricemia increases SHPT risk is not completely understood.
Parathyroidectomy May Improve Quality of Life in Dialysis Population
The indications for parathyroidectomy included uncontrolled pruritus, bone pain, resistance to medical treatment, and intact PTH levels exceeding 1000 pg/mL.
Urgent Hemodialysis Feasible for Perioperative Hyperkalemia in PTx Cases
Perioperative management of serum potassium levels is crucial in patients with kidney failure undergoing parathyroidectomy.
Parathyroidectomy for SHPT Offers Better Survival vs Cinacalcet, Data Show
The study findings may help guide decision-making for clinicians caring for patients who receive hemodialysis or kidney transplant with severe secondary hyperparathyroidism.
- Loading...
Loading...
Next post in Secondary Hyperparathyroidism
Loading... 
Loading...